Type of security: Stock
Sector: Capital Goods
The data is delayed by 15 minutes.
IART is in the long-term up 319% in 14 years.
Description: Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. Its orthopedics products include specialty metal implants for surgery of the extremities, shoulder, and spine; orthobiologic products for repair and grafting of bone, including demineralized bone products, collagen ceramic matrices, and synthetic bone grafting solutions; dermal regeneration products and tissue-engineered wound dressings; and nerve and tendon repair products. The company also offers spinal fusion technologies comprising integrated interbody fusion devices, minimally invasive solutions, and deformity correction products; and neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devi
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||1%||Sales Growth - Q/Q||-7.34%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||2.59%||ROE||5.84%||ROI||3.02%|
|Current Ratio||4.12||Quick Ratio||2.28||Long Term Debt/Equity||1.55||Debt Ratio||0.18|
|Gross Margin||62.28%||Operating Margin||7.77%||Net Profit Margin||4.24%||Dividend Payout Ratio|
|Cash From Financing Activities||30.45 M||Cash From Investing Activities||-18.74 M||Cash From Operating Activities||49.74 M||Gross Profit||157.54 M|
|Net Profit||5 M||Operating Profit||13.95 M||Total Assets||1.64 B||Total Current Assets||608.25 M|
|Total Current Liabilities||155.75 M||Total Debt||654.14 M||Total Liabilities||926.17 M||Total Revenue||244.08 M|
|High 52 week||65.87||Low 52 week||42.62||Last close||61.85||Last change||2.11%|
|RSI||53.53||Average true range||1.4||Beta||0.67||Volume||390.34 K|
|Simple moving average 20 days||2.95%||Simple moving average 50 days||2.07%||Simple moving average 200 days||13.93%|
|Performance Week||6.77%||Performance Month||1.76%||Performance Quart||14.66%||Performance Half||17.45%|
|Performance Year||-3.1%||Performance Year-to-date||37.14%||Volatility daily||1.4%||Volatility weekly||3.13%|
|Volatility monthly||6.42%||Volatility yearly||22.25%||Relative Volume||322.8%||Average Volume||416.06 K|
|New High||New Low|
2021-09-02 16:01:00 | Integra LifeSciences Announces Participation in Upcoming Investor Conferences
2021-09-02 10:07:23 | Is It Too Late To Consider Buying Integra LifeSciences Holdings Corporation NASDAQ:IART?
2021-08-27 11:31:03 | Integra IART Up 1.5% Since Last Earnings Report: Can It Continue?
2021-08-27 09:19:01 | Here's Why You Should Retain Integra IART Stock for Now
2021-08-03 09:33:01 | Integra LifeSciences IART is a Top-Ranked Momentum Stock: Should You Buy?
2021-07-29 08:29:12 | Integra IART Q2 Earnings Top Estimates, 2021 Guidance Up
2021-07-28 14:00:41 | Integra LifeSciences Holdings Corporation IART Q2 2021 Earnings Call Transcript
2021-07-28 07:15:11 | Integra LifeSciences IART Tops Q2 Earnings and Revenue Estimates
2021-07-28 06:00:00 | Integra LifeSciences Reports Second Quarter 2021 Financial Results
2021-07-27 10:53:02 | Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More
2021-07-21 15:02:07 | Integra LifeSciences IART Earnings Expected to Grow: Should You Buy?
2021-07-20 06:59:10 | Integra IART Releases Favorable PriMatrix Clinical Outcome
2021-07-15 08:27:12 | Integra's IART SurgiMend Gets Innovative Technology Contract
2021-06-24 08:30:00 | Integra LifeSciences Announces CEO Succession Plan
2021-06-13 04:44:11 | Is Now The Time To Put Integra LifeSciences Holdings NASDAQ:IART On Your Watchlist?
2021-06-01 09:32:01 | Integra IART Tissue Technologies Rebounds Amid Supply Woe
2021-05-28 11:32:03 | Integra IART Down 8.1% Since Last Earnings Report: Can It Rebound?
2021-05-20 06:00:00 | Integra LifeSciences Hosts Virtual Investor Day
2021-05-07 08:30:00 | Integra LifeSciences to Host Virtual Investor Day on May 20, 2021
2021-04-30 10:04:02 | ResMed RMD Q3 Earnings Surpass Estimates, Revenues Miss
2021-04-30 09:29:01 | Bio-Rad BIO Q1 Earnings Surpass Estimates, Guidance Up
2021-04-30 09:01:01 | Syneos Health SYNH Q1 Earnings Top Estimates, Margins Up
2021-04-29 09:15:01 | Integra IART Hits Fresh High: Is There Still Room to Run?
2021-04-29 09:04:01 | Integra IART Q1 Earnings Beat Estimates, Gross Margin Down
2021-04-28 19:30:41 | Integra Lifesciences Holdings Corp IART Q1 2021 Earnings Call Transcript
2021-04-28 07:30:11 | Integra LifeSciences IART Q1 Earnings and Revenues Top Estimates
2021-04-28 06:45:00 | Integra LifeSciences Holdings Corp. to Host Earnings Call
2021-04-28 06:00:00 | Integra LifeSciences Reports First Quarter 2021 Financial Results
2021-04-27 08:56:12 | Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More
2021-04-22 10:59:02 | Integra IART to Report Q1 Earnings: What's in the Offing?
2021-04-20 09:49:01 | Abbott ABT Q1 Earnings Miss, Diagnostic Test Sales Solid
2021-04-20 08:09:12 | Integra IART Hits New 52-Week High: What's Driving It?
2021-04-03 05:30:56 | Is Integra LifeSciences Holdings Corporation's NASDAQ:IART 8.8% ROE Worse Than Average?
2021-04-01 16:15:00 | Integra LifeSciences Appoints Shaundra Clay as Director
2021-03-31 10:41:02 | Here's Why You Should Retain Integra LifeSciences IART Stock
2021-03-31 09:08:01 | Integra's IART Neurosurgery Rebounds Despite Supply Issues
2021-03-22 05:33:09 | Veeva VEEV Partners With Impel, Boosts Cloud-Based Offerings Revised
2021-03-20 11:30:03 | Integra IART Down 3% Since Last Earnings Report: Can It Rebound?
2021-03-10 09:24:02 | Integra IART Neurosurgery Grows Sequentially Amid Supply Woe
2021-02-19 08:00:00 | Integra LifeSciences Announces Participation in Upcoming Investor Conferences
2021-02-18 16:00:43 | Integra Lifesciences Holdings Corp IART Q4 2020 Earnings Call Transcript